Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases

Patents filed for the company's most advanced programs in lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) All novel mechanisms of action have demonstrated positive efficacy data in industry standard animal pharmacology models PALO ALTO, Calif., Aug. 30, 2022...

Click to view original post